secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001104659-23-077074
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics completes $19M sale of manufacturing facilities to Cell Ready, exits manufacturing operations
--------------------------------------------------------------------------------

- Completed disposition of manufacturing facilities and equipment to Cell Ready for $19M on June 26, 2023.
- Transaction includes assignment of leases and sale of equipment; Cell Ready to offer employment to ~50 Marker employees.
- Pro forma results show net loss per share improvement: Q1 2023 by $0.01, FY2022 by $1.18, FY2021 by $2.11.
- Pro forma cash and cash equivalents increased to $25.2M from $6.4M as of March 31, 2023.
- John Wilson, Marker board member, is CEO and sole member of Cell Ready, creating a related-party transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/0001104659-23-077074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/tm2319618d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-077074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer